Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfasalazine for Preventing Recurrent Preterm Birth
NCT05703425Phase 2Recruiting
- Sponsor
- Rutgers University
- Start
- Mar 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of 5-aminosalicylic acid + sulphasalazine in preterm birth (2 arms), sponsored by Rutgers University. Primary endpoint: Serum corticotropin releasing hormone levels at 36 weeks. Started Mar 2023; status: recruiting.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
preterm birth
Beyond the preview
Go deeper on NCT05703425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703425.